A New Look at an Old Drug for a Dangerous Pregnancy Complication
A recent proof-of-concept clinical trial in Australia has investigated the safety and pharmacokinetics of sulfasalazine for treating preterm preeclampsia. The study found the drug was well tolerated in pregnant women with this condition, with evidence of both maternal and fetal exposure and clear placental transfer. These initial findings establish the feasibility of using sulfasalazine in this high-risk population and provide the necessary groundwork to justify a larger, efficacy-focused clinical trial.
Why it might matter to you: For nephrologists managing complex hypertension and kidney function in pregnancy, this research points to a potential future therapeutic avenue for preeclampsia, a major cause of acute kidney injury and maternal morbidity. Understanding the pharmacokinetics and placental transfer of repurposed drugs is critical for assessing their renal safety profile and potential nephroprotective effects in this vulnerable patient group. This development underscores the ongoing need to bridge obstetrical and renal medicine in managing pregnancy-related kidney complications.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
